Eva Burnett

Most-cited papers

1. ICON 9—an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy

   O. Elyashiv, J. Ledermann, G. Parmar, L. Farrelly +11 more

   2020International Journal of Gynecological Cancer24 citations Open access

   Semantic Scholar

   Save

2. The SHOW RESPECT adaptable framework of considerations for planning how to share trial results with participants, based on qualitative findings from trial participants and site staff

   Annabelle South, C. Snowdon, Eva Burnett, B. Bierer +3 more

   2024Trials5 citations Open access

   Semantic Scholar

   Save

3. Site staff perspectives on communicating trial results to participants: Cost and feasibility results from the Show RESPECT cluster randomised, factorial, mixed-methods trial

   A. South, Julia V. Bailey, B. Bierer, Eva Burnett +8 more

   2023Clinical Trials4 citations Open access

   Semantic Scholar

   Save

4. Language-related eligibility criteria in UK randomised trials: a systematic review of extended research reports

   T. Isaacs, Andrea Vaughan, Eva Burnett, Z. Demjén +8 more

   2026Trials0 citations Open access

   Semantic Scholar

   Save

5. ICON 9- An international phase III randomised study to evaluate the 1 efficacy of maintenance therapy with olaparib and cediranib or olaparib 2 alone in patients with relapsed platinum-sensitive ovarian cancer following 3 a response to platinum-based chemotherapy .

   O. Elyashiv, J. Ledermann, G. Parmar, L. Farrelly +11 more

   20200 citations

   Semantic Scholar

   Save